Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Food Allergen OIT for Shrimp and Cashew
A prospective Phase 2, single-center, single-allergen OIT of cashew or shrimp in participants with proven allergies to either cashew or shrimp, respectively. We intend to treat 72 participants, ages 7 to 55 years with an allergy to either cashew, or shrimp determined by Double Blind-Placebo Controlled-Food Challenge (DBPCFC), allergy history, clinical symptoms, food-allergen (FA)-specific IgE levels, and skin prick test (SPT).
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Cashew or Shrimp Oral Immunotherapy
Eligibility
Inclusion Criteria:
- Subject and/or parent guardian must be able to understand and provide informed consent
- Age 7 through 55 years (inclusive)
- Clinical history of allergy to cashew or shrimp-containing foods
- Serum IgE to cashew or shrimp of ≥0.35 kUA/L [determined by UniCAPTM within the past
12 months] and/or a SPT to cashew or shrimp ≥3 mm compared to control
- Experience dose-limiting symptoms at or before the 300 mg challenge dose of FA protein
on Screening DBPCFC conducted in accordance with PRACTALL guidelines
- Written informed consent from adult participants
- Written informed consent from parent/guardian for minor participants
- Written assent from minor participants as appropriate (e.g., above the age of 7 years
or the applicable age per local regulatory requirements)
- All female subjects of child-bearing potential will be required to provide a blood or
urine sample for pregnancy testing that must be negative one week before being allowed
to participate in the study.
- Use of effective birth control by female participants of child-bearing potential.
Exclusion Criteria:
- Inability or unwillingness of a participant to give written informed consent or comply
with study protocol
- History of uncontrolled cardiovascular disease, including uncontrolled hypertension
- History of other chronic disease (other than asthma, atopic dermatitis, or allergic
rhinitis) requiring therapy (e.g., heart disease, diabetes) that is, or is at
significant risk of becoming unstable or requiring a change in chronic therapeutic
regimen and, in the opinion of the Principal Investigator, would represent a risk to
the subject's health or safety in this study or the subject's ability to comply with
the study protocol.
- History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal
disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD) grade 3
according to CTCAE version 5.0, symptoms of dysphagia (e.g., difficulty swallowing,
food "getting stuck"), or recurrent gastrointestinal symptoms of undiagnosed etiology
- Current participation in any other interventional study
- Subject is currently in the build-up phase of immunotherapy to another allergen and is
on maintenance immunotherapy dose for any allergen related to cashew or shrimp
- Severe asthma (NAEPP EPR-3 Medication Criteria Steps 5 or 6)
- Mild or moderate asthma (NAEPP EPR-3 Medication Criteria Steps 1-4), if not controlled
as indicated by an ACT<19
- A hospitalization for asthma in the past 6 months
- ER visit for asthma within the past 6 months
- Burst or steroid course for asthma in the past 6 months
- Use of omalizumab or biologic therapy (e.g., infliximab, rituximab, etc.) within the
past 6 months
- Use of complementary and alternative medicine (CAM) treatment modalities (e.g., herbal
remedies) for atopic and /or non-atopic disease within 90 days preceding Initial Dose
Escalation Day (IDED) or at any time after the IDED
- Use of beta-blockers (oral)
- Pregnancy or lactation
- Allergy to oat
- History of severe anaphylaxis to cashew or shrimp with symptoms including hypotension
requiring fluid resuscitation and/or the need for mechanical ventilation within the
last year
- Use of investigational drugs within 12 weeks of participation
- Past or current medical problems or findings from physical assessment or laboratory
testing that are not listed above, which, in the opinion of the investigator, may pose
additional risks from participation in the study, may interfere with the participant's
ability to comply with study requirements or that may impact the quality or
interpretation of the data obtained from the study
Ages Eligible for Study
7 Years - 55 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting
Psoriasis Clinical Trials
Food Allergen OIT for Shrimp and Cashew
A prospective Phase 2, single-center, single-allergen OIT of cashew or shrimp in participants with proven allergies to either cashew or shrimp, respectively. We intend to treat 72 participants, ages 7 to 55 years with an allergy to either cashew, or shrimp determined by Double Blind-Placebo Controlled-Food Challenge (DBPCFC), allergy history, clinical symptoms, food-allergen (FA)-specific IgE levels, and skin prick test (SPT).
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Cashew or Shrimp Oral Immunotherapy
Eligibility
Inclusion Criteria:
- Subject and/or parent guardian must be able to understand and provide informed consent
- Age 7 through 55 years (inclusive)
- Clinical history of allergy to cashew or shrimp-containing foods
- Serum IgE to cashew or shrimp of ≥0.35 kUA/L [determined by UniCAPTM within the past
12 months] and/or a SPT to cashew or shrimp ≥3 mm compared to control
- Experience dose-limiting symptoms at or before the 300 mg challenge dose of FA protein
on Screening DBPCFC conducted in accordance with PRACTALL guidelines
- Written informed consent from adult participants
- Written informed consent from parent/guardian for minor participants
- Written assent from minor participants as appropriate (e.g., above the age of 7 years
or the applicable age per local regulatory requirements)
- All female subjects of child-bearing potential will be required to provide a blood or
urine sample for pregnancy testing that must be negative one week before being allowed
to participate in the study.
- Use of effective birth control by female participants of child-bearing potential.
Exclusion Criteria:
- Inability or unwillingness of a participant to give written informed consent or comply
with study protocol
- History of uncontrolled cardiovascular disease, including uncontrolled hypertension
- History of other chronic disease (other than asthma, atopic dermatitis, or allergic
rhinitis) requiring therapy (e.g., heart disease, diabetes) that is, or is at
significant risk of becoming unstable or requiring a change in chronic therapeutic
regimen and, in the opinion of the Principal Investigator, would represent a risk to
the subject's health or safety in this study or the subject's ability to comply with
the study protocol.
- History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal
disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD) grade 3
according to CTCAE version 5.0, symptoms of dysphagia (e.g., difficulty swallowing,
food "getting stuck"), or recurrent gastrointestinal symptoms of undiagnosed etiology
- Current participation in any other interventional study
- Subject is currently in the build-up phase of immunotherapy to another allergen and is
on maintenance immunotherapy dose for any allergen related to cashew or shrimp
- Severe asthma (NAEPP EPR-3 Medication Criteria Steps 5 or 6)
- Mild or moderate asthma (NAEPP EPR-3 Medication Criteria Steps 1-4), if not controlled
as indicated by an ACT<19
- A hospitalization for asthma in the past 6 months
- ER visit for asthma within the past 6 months
- Burst or steroid course for asthma in the past 6 months
- Use of omalizumab or biologic therapy (e.g., infliximab, rituximab, etc.) within the
past 6 months
- Use of complementary and alternative medicine (CAM) treatment modalities (e.g., herbal
remedies) for atopic and /or non-atopic disease within 90 days preceding Initial Dose
Escalation Day (IDED) or at any time after the IDED
- Use of beta-blockers (oral)
- Pregnancy or lactation
- Allergy to oat
- History of severe anaphylaxis to cashew or shrimp with symptoms including hypotension
requiring fluid resuscitation and/or the need for mechanical ventilation within the
last year
- Use of investigational drugs within 12 weeks of participation
- Past or current medical problems or findings from physical assessment or laboratory
testing that are not listed above, which, in the opinion of the investigator, may pose
additional risks from participation in the study, may interfere with the participant's
ability to comply with study requirements or that may impact the quality or
interpretation of the data obtained from the study
Ages Eligible for Study
7 Years - 55 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting
Dermatology Clinical Trials
Food Allergen OIT for Shrimp and Cashew
A prospective Phase 2, single-center, single-allergen OIT of cashew or shrimp in participants with proven allergies to either cashew or shrimp, respectively. We intend to treat 72 participants, ages 7 to 55 years with an allergy to either cashew, or shrimp determined by Double Blind-Placebo Controlled-Food Challenge (DBPCFC), allergy history, clinical symptoms, food-allergen (FA)-specific IgE levels, and skin prick test (SPT).
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Cashew or Shrimp Oral Immunotherapy
Eligibility
Inclusion Criteria:
- Subject and/or parent guardian must be able to understand and provide informed consent
- Age 7 through 55 years (inclusive)
- Clinical history of allergy to cashew or shrimp-containing foods
- Serum IgE to cashew or shrimp of ≥0.35 kUA/L [determined by UniCAPTM within the past
12 months] and/or a SPT to cashew or shrimp ≥3 mm compared to control
- Experience dose-limiting symptoms at or before the 300 mg challenge dose of FA protein
on Screening DBPCFC conducted in accordance with PRACTALL guidelines
- Written informed consent from adult participants
- Written informed consent from parent/guardian for minor participants
- Written assent from minor participants as appropriate (e.g., above the age of 7 years
or the applicable age per local regulatory requirements)
- All female subjects of child-bearing potential will be required to provide a blood or
urine sample for pregnancy testing that must be negative one week before being allowed
to participate in the study.
- Use of effective birth control by female participants of child-bearing potential.
Exclusion Criteria:
- Inability or unwillingness of a participant to give written informed consent or comply
with study protocol
- History of uncontrolled cardiovascular disease, including uncontrolled hypertension
- History of other chronic disease (other than asthma, atopic dermatitis, or allergic
rhinitis) requiring therapy (e.g., heart disease, diabetes) that is, or is at
significant risk of becoming unstable or requiring a change in chronic therapeutic
regimen and, in the opinion of the Principal Investigator, would represent a risk to
the subject's health or safety in this study or the subject's ability to comply with
the study protocol.
- History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal
disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD) grade 3
according to CTCAE version 5.0, symptoms of dysphagia (e.g., difficulty swallowing,
food "getting stuck"), or recurrent gastrointestinal symptoms of undiagnosed etiology
- Current participation in any other interventional study
- Subject is currently in the build-up phase of immunotherapy to another allergen and is
on maintenance immunotherapy dose for any allergen related to cashew or shrimp
- Severe asthma (NAEPP EPR-3 Medication Criteria Steps 5 or 6)
- Mild or moderate asthma (NAEPP EPR-3 Medication Criteria Steps 1-4), if not controlled
as indicated by an ACT<19
- A hospitalization for asthma in the past 6 months
- ER visit for asthma within the past 6 months
- Burst or steroid course for asthma in the past 6 months
- Use of omalizumab or biologic therapy (e.g., infliximab, rituximab, etc.) within the
past 6 months
- Use of complementary and alternative medicine (CAM) treatment modalities (e.g., herbal
remedies) for atopic and /or non-atopic disease within 90 days preceding Initial Dose
Escalation Day (IDED) or at any time after the IDED
- Use of beta-blockers (oral)
- Pregnancy or lactation
- Allergy to oat
- History of severe anaphylaxis to cashew or shrimp with symptoms including hypotension
requiring fluid resuscitation and/or the need for mechanical ventilation within the
last year
- Use of investigational drugs within 12 weeks of participation
- Past or current medical problems or findings from physical assessment or laboratory
testing that are not listed above, which, in the opinion of the investigator, may pose
additional risks from participation in the study, may interfere with the participant's
ability to comply with study requirements or that may impact the quality or
interpretation of the data obtained from the study
Ages Eligible for Study
7 Years - 55 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting
Pediatric Dermatology Clinical Trials
Food Allergen OIT for Shrimp and Cashew
A prospective Phase 2, single-center, single-allergen OIT of cashew or shrimp in participants with proven allergies to either cashew or shrimp, respectively. We intend to treat 72 participants, ages 7 to 55 years with an allergy to either cashew, or shrimp determined by Double Blind-Placebo Controlled-Food Challenge (DBPCFC), allergy history, clinical symptoms, food-allergen (FA)-specific IgE levels, and skin prick test (SPT).
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Cashew or Shrimp Oral Immunotherapy
Eligibility
Inclusion Criteria:
- Subject and/or parent guardian must be able to understand and provide informed consent
- Age 7 through 55 years (inclusive)
- Clinical history of allergy to cashew or shrimp-containing foods
- Serum IgE to cashew or shrimp of ≥0.35 kUA/L [determined by UniCAPTM within the past
12 months] and/or a SPT to cashew or shrimp ≥3 mm compared to control
- Experience dose-limiting symptoms at or before the 300 mg challenge dose of FA protein
on Screening DBPCFC conducted in accordance with PRACTALL guidelines
- Written informed consent from adult participants
- Written informed consent from parent/guardian for minor participants
- Written assent from minor participants as appropriate (e.g., above the age of 7 years
or the applicable age per local regulatory requirements)
- All female subjects of child-bearing potential will be required to provide a blood or
urine sample for pregnancy testing that must be negative one week before being allowed
to participate in the study.
- Use of effective birth control by female participants of child-bearing potential.
Exclusion Criteria:
- Inability or unwillingness of a participant to give written informed consent or comply
with study protocol
- History of uncontrolled cardiovascular disease, including uncontrolled hypertension
- History of other chronic disease (other than asthma, atopic dermatitis, or allergic
rhinitis) requiring therapy (e.g., heart disease, diabetes) that is, or is at
significant risk of becoming unstable or requiring a change in chronic therapeutic
regimen and, in the opinion of the Principal Investigator, would represent a risk to
the subject's health or safety in this study or the subject's ability to comply with
the study protocol.
- History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal
disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD) grade 3
according to CTCAE version 5.0, symptoms of dysphagia (e.g., difficulty swallowing,
food "getting stuck"), or recurrent gastrointestinal symptoms of undiagnosed etiology
- Current participation in any other interventional study
- Subject is currently in the build-up phase of immunotherapy to another allergen and is
on maintenance immunotherapy dose for any allergen related to cashew or shrimp
- Severe asthma (NAEPP EPR-3 Medication Criteria Steps 5 or 6)
- Mild or moderate asthma (NAEPP EPR-3 Medication Criteria Steps 1-4), if not controlled
as indicated by an ACT<19
- A hospitalization for asthma in the past 6 months
- ER visit for asthma within the past 6 months
- Burst or steroid course for asthma in the past 6 months
- Use of omalizumab or biologic therapy (e.g., infliximab, rituximab, etc.) within the
past 6 months
- Use of complementary and alternative medicine (CAM) treatment modalities (e.g., herbal
remedies) for atopic and /or non-atopic disease within 90 days preceding Initial Dose
Escalation Day (IDED) or at any time after the IDED
- Use of beta-blockers (oral)
- Pregnancy or lactation
- Allergy to oat
- History of severe anaphylaxis to cashew or shrimp with symptoms including hypotension
requiring fluid resuscitation and/or the need for mechanical ventilation within the
last year
- Use of investigational drugs within 12 weeks of participation
- Past or current medical problems or findings from physical assessment or laboratory
testing that are not listed above, which, in the opinion of the investigator, may pose
additional risks from participation in the study, may interfere with the participant's
ability to comply with study requirements or that may impact the quality or
interpretation of the data obtained from the study
Ages Eligible for Study
7 Years - 55 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting
Food Allergen OIT for Shrimp and Cashew
A prospective Phase 2, single-center, single-allergen OIT of cashew or shrimp in participants with proven allergies to either cashew or shrimp, respectively. We intend to treat 72 participants, ages 7 to 55 years with an allergy to either cashew, or shrimp determined by Double Blind-Placebo Controlled-Food Challenge (DBPCFC), allergy history, clinical symptoms, food-allergen (FA)-specific IgE levels, and skin prick test (SPT).
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Cashew or Shrimp Oral Immunotherapy
Eligibility
Inclusion Criteria:
- Subject and/or parent guardian must be able to understand and provide informed consent
- Age 7 through 55 years (inclusive)
- Clinical history of allergy to cashew or shrimp-containing foods
- Serum IgE to cashew or shrimp of ≥0.35 kUA/L [determined by UniCAPTM within the past
12 months] and/or a SPT to cashew or shrimp ≥3 mm compared to control
- Experience dose-limiting symptoms at or before the 300 mg challenge dose of FA protein
on Screening DBPCFC conducted in accordance with PRACTALL guidelines
- Written informed consent from adult participants
- Written informed consent from parent/guardian for minor participants
- Written assent from minor participants as appropriate (e.g., above the age of 7 years
or the applicable age per local regulatory requirements)
- All female subjects of child-bearing potential will be required to provide a blood or
urine sample for pregnancy testing that must be negative one week before being allowed
to participate in the study.
- Use of effective birth control by female participants of child-bearing potential.
Exclusion Criteria:
- Inability or unwillingness of a participant to give written informed consent or comply
with study protocol
- History of uncontrolled cardiovascular disease, including uncontrolled hypertension
- History of other chronic disease (other than asthma, atopic dermatitis, or allergic
rhinitis) requiring therapy (e.g., heart disease, diabetes) that is, or is at
significant risk of becoming unstable or requiring a change in chronic therapeutic
regimen and, in the opinion of the Principal Investigator, would represent a risk to
the subject's health or safety in this study or the subject's ability to comply with
the study protocol.
- History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal
disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD) grade 3
according to CTCAE version 5.0, symptoms of dysphagia (e.g., difficulty swallowing,
food "getting stuck"), or recurrent gastrointestinal symptoms of undiagnosed etiology
- Current participation in any other interventional study
- Subject is currently in the build-up phase of immunotherapy to another allergen and is
on maintenance immunotherapy dose for any allergen related to cashew or shrimp
- Severe asthma (NAEPP EPR-3 Medication Criteria Steps 5 or 6)
- Mild or moderate asthma (NAEPP EPR-3 Medication Criteria Steps 1-4), if not controlled
as indicated by an ACT<19
- A hospitalization for asthma in the past 6 months
- ER visit for asthma within the past 6 months
- Burst or steroid course for asthma in the past 6 months
- Use of omalizumab or biologic therapy (e.g., infliximab, rituximab, etc.) within the
past 6 months
- Use of complementary and alternative medicine (CAM) treatment modalities (e.g., herbal
remedies) for atopic and /or non-atopic disease within 90 days preceding Initial Dose
Escalation Day (IDED) or at any time after the IDED
- Use of beta-blockers (oral)
- Pregnancy or lactation
- Allergy to oat
- History of severe anaphylaxis to cashew or shrimp with symptoms including hypotension
requiring fluid resuscitation and/or the need for mechanical ventilation within the
last year
- Use of investigational drugs within 12 weeks of participation
- Past or current medical problems or findings from physical assessment or laboratory
testing that are not listed above, which, in the opinion of the investigator, may pose
additional risks from participation in the study, may interfere with the participant's
ability to comply with study requirements or that may impact the quality or
interpretation of the data obtained from the study
Ages Eligible for Study
7 Years - 55 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting
Food Allergen OIT for Shrimp and Cashew
A prospective Phase 2, single-center, single-allergen OIT of cashew or shrimp in participants with proven allergies to either cashew or shrimp, respectively. We intend to treat 72 participants, ages 7 to 55 years with an allergy to either cashew, or shrimp determined by Double Blind-Placebo Controlled-Food Challenge (DBPCFC), allergy history, clinical symptoms, food-allergen (FA)-specific IgE levels, and skin prick test (SPT).
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Cashew or Shrimp Oral Immunotherapy
Eligibility
Inclusion Criteria:
- Subject and/or parent guardian must be able to understand and provide informed consent
- Age 7 through 55 years (inclusive)
- Clinical history of allergy to cashew or shrimp-containing foods
- Serum IgE to cashew or shrimp of ≥0.35 kUA/L [determined by UniCAPTM within the past
12 months] and/or a SPT to cashew or shrimp ≥3 mm compared to control
- Experience dose-limiting symptoms at or before the 300 mg challenge dose of FA protein
on Screening DBPCFC conducted in accordance with PRACTALL guidelines
- Written informed consent from adult participants
- Written informed consent from parent/guardian for minor participants
- Written assent from minor participants as appropriate (e.g., above the age of 7 years
or the applicable age per local regulatory requirements)
- All female subjects of child-bearing potential will be required to provide a blood or
urine sample for pregnancy testing that must be negative one week before being allowed
to participate in the study.
- Use of effective birth control by female participants of child-bearing potential.
Exclusion Criteria:
- Inability or unwillingness of a participant to give written informed consent or comply
with study protocol
- History of uncontrolled cardiovascular disease, including uncontrolled hypertension
- History of other chronic disease (other than asthma, atopic dermatitis, or allergic
rhinitis) requiring therapy (e.g., heart disease, diabetes) that is, or is at
significant risk of becoming unstable or requiring a change in chronic therapeutic
regimen and, in the opinion of the Principal Investigator, would represent a risk to
the subject's health or safety in this study or the subject's ability to comply with
the study protocol.
- History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal
disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD) grade 3
according to CTCAE version 5.0, symptoms of dysphagia (e.g., difficulty swallowing,
food "getting stuck"), or recurrent gastrointestinal symptoms of undiagnosed etiology
- Current participation in any other interventional study
- Subject is currently in the build-up phase of immunotherapy to another allergen and is
on maintenance immunotherapy dose for any allergen related to cashew or shrimp
- Severe asthma (NAEPP EPR-3 Medication Criteria Steps 5 or 6)
- Mild or moderate asthma (NAEPP EPR-3 Medication Criteria Steps 1-4), if not controlled
as indicated by an ACT<19
- A hospitalization for asthma in the past 6 months
- ER visit for asthma within the past 6 months
- Burst or steroid course for asthma in the past 6 months
- Use of omalizumab or biologic therapy (e.g., infliximab, rituximab, etc.) within the
past 6 months
- Use of complementary and alternative medicine (CAM) treatment modalities (e.g., herbal
remedies) for atopic and /or non-atopic disease within 90 days preceding Initial Dose
Escalation Day (IDED) or at any time after the IDED
- Use of beta-blockers (oral)
- Pregnancy or lactation
- Allergy to oat
- History of severe anaphylaxis to cashew or shrimp with symptoms including hypotension
requiring fluid resuscitation and/or the need for mechanical ventilation within the
last year
- Use of investigational drugs within 12 weeks of participation
- Past or current medical problems or findings from physical assessment or laboratory
testing that are not listed above, which, in the opinion of the investigator, may pose
additional risks from participation in the study, may interfere with the participant's
ability to comply with study requirements or that may impact the quality or
interpretation of the data obtained from the study
Ages Eligible for Study
7 Years - 55 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting